• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Kusserow Paul B. K. was granted 1,690 shares (SEC Form 4)

    5/6/25 8:24:03 PM ET
    $AMED
    Medical/Nursing Services
    Health Care
    Get the next $AMED alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Kusserow Paul B. K.

    (Last) (First) (Middle)
    3854 AMERICAN WAY, SUITE A

    (Street)
    BATON ROUGE LA 70816

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    AMEDISYS INC [ AMED ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/03/2025 A 1,690 A $0 439,124(1) I By Trust
    Common Stock 621(2) I Through 401(k) Plan
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Includes shares previously held directly and are now owned indirectly through a trust in which the reporting person is the grantor, trustee and beneficiary.
    2. The information in this report is based on a plan statement dated as of March 31, 2025.
    Remarks:
    Jennifer Guckert Griffin, pursuant to a power of attorney 05/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AMED alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMED

    DatePrice TargetRatingAnalyst
    7/29/2024$101.00Buy → Hold
    Deutsche Bank
    7/1/2024Outperform → Mkt Perform
    William Blair
    6/7/2023$97.00Buy → Hold
    Truist
    4/21/2023$87.00Neutral
    Cantor Fitzgerald
    3/13/2023$93.00Equal Weight
    Barclays
    10/27/2022Outperform → Mkt Perform
    Raymond James
    8/2/2022$145.00 → $95.00Neutral → Sell
    UBS
    6/29/2022$128.00Hold
    Stifel
    More analyst ratings

    $AMED
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amedisys Reports First Quarter 2025 Financial Results

      BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2025. Three-Month Periods Ended March 31, 2025 and 2024 Net service revenue increased $23.4 million to $594.8 million compared to $571.4 million in 2024.Net income attributable to Amedisys, Inc. of $61.0 million, which is inclusive of merger-related expenses totaling $16.8 million ($16.6 million, net of tax) and a $48.1 million gain on an equity method investment ($35.6 million, net of tax), compared to net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 milli

      4/23/25 4:45:43 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Reports Fourth Quarter and Year End 2024 Financial Results

      BATON ROUGE, La., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2024. Three-Month Periods Ended December 31, 2024 and 2023 Net service revenue increased $27.3 million to $598.1 million compared to $570.8 million in 2023.Net loss attributable to Amedisys, Inc. of $20.4 million, which is inclusive of merger-related expenses totaling $17.4 million ($15.9 million, net of tax) and a non-cash goodwill and other intangibles impairment charge totaling $48.4 million ($38.4 million, net of noncontrolling interest and tax) compared to net income attributable to Amedisys, Inc. of $19.3 milli

      2/26/25 4:30:12 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Honors 47 Employees With Annual Spirit of Excellence Award

      BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company's highest honors. "Every day, our employees bring warmth, compassion and clinical expertise into the homes of our patients, offering the care they need in the place they most want to be," said Richard Ashworth, President and Chief Executive Officer. "We are privileged to have exceptional clinicians who consistently exceed expectations, and it is a profound honor to recognize their incredible commitment." Each year, the company honors Home

      2/3/25 6:30:00 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

      SC 13G/A - AMEDISYS INC (0000896262) (Subject)

      2/13/24 4:58:48 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

      SC 13G/A - AMEDISYS INC (0000896262) (Subject)

      2/12/24 5:24:28 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

      SC 13G/A - AMEDISYS INC (0000896262) (Subject)

      2/8/24 10:18:47 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Guidroz Allyson covered exercise/tax liability with 273 shares, decreasing direct ownership by 3% to 8,488 units (SEC Form 4)

      4 - AMEDISYS INC (0000896262) (Issuer)

      5/6/25 8:24:14 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Director Kusserow Paul B. K. was granted 1,690 shares (SEC Form 4)

      4 - AMEDISYS INC (0000896262) (Issuer)

      5/6/25 8:24:03 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Director Kline Teresa L. was granted 1,690 shares, increasing direct ownership by 21% to 9,818 units (SEC Form 4)

      4 - AMEDISYS INC (0000896262) (Issuer)

      5/6/25 7:49:02 PM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amedisys downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Amedisys from Buy to Hold and set a new price target of $101.00

      7/29/24 7:29:37 AM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys downgraded by William Blair

      William Blair downgraded Amedisys from Outperform to Mkt Perform

      7/1/24 7:29:43 AM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys downgraded by Truist with a new price target

      Truist downgraded Amedisys from Buy to Hold and set a new price target of $97.00

      6/7/23 9:03:46 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    SEC Filings

    See more
    • SEC Form 8-K filed by Amedisys Inc

      8-K - AMEDISYS INC (0000896262) (Filer)

      5/1/25 5:00:16 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form 10-K/A filed by Amedisys Inc

      10-K/A - AMEDISYS INC (0000896262) (Filer)

      4/29/25 4:12:39 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • SEC Form 10-Q filed by Amedisys Inc

      10-Q - AMEDISYS INC (0000896262) (Filer)

      4/24/25 8:02:23 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Financials

    Live finance-specific insights

    See more
    • AMEDISYS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES 2023 GUIDANCE

      BATON ROUGE, La., May 3, 2023 /PRNewswire/ -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2023. Three-Month Periods Ended March 31, 2023 and 2022 Net service revenue increased $11.1 million to $556.4 million compared to $545.3 million in 2022.Net income attributable to Amedisys, Inc. of $25.2 million compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted share of $0.77 compared to $0.97 in 2022.Adjusted Quarterly Results* Adjusted EBITDA of $57.8 million compared to $66.3 million

      5/3/23 4:31:00 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Option Care Health and Amedisys to Combine Creating a Leading, Independent Platform for Home and Alternate Site Care

      All-Stock Transaction Combines Highly Complementary Businesses Unlocking Significant Benefits for Patients, Providers, Payers, and Care Teams Increases Access to High Quality Care for Communities Across the U.S. through a Unique National Clinical Platform Comprehensive Capabilities Across Alternate Site Care Spectrum Position Combined Company to Move Deeper into Value-Based Care Highly Attractive Combined Financial Profile Which Generated $6.2 Billion in Revenues and $622 Million in Adjusted EBITDA on a Combined Basis for Full Year 2022 Creates Stockholder Value Including Through Anticipated Annual Run-Rate Revenue and Cost Synergies of Approximately $75 Million by Year Three Following Clo

      5/3/23 4:30:00 PM ET
      $AMED
      $OPCH
      Medical/Nursing Services
      Health Care
    • Amedisys Announces First Quarter 2023 Earnings Release and Conference Call Date

      BATON ROUGE, La., April 20, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care, will report results for the first quarter ended March 31, 2023, after the market closes on May 3, 2023. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 4, 2023. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (888) 437-3179 (toll-free) or (862) 298-0702 (toll). A replay of the call will be available through June 4, 2023, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13737736. To access a live webcast of th

      4/20/23 8:00:00 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Leadership Updates

    Live Leadership Updates

    See more
    • Amedisys Reports Second Quarter 2024 Financial Results

      BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023.Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) compared to net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of merger-related expenses totaling $125.5 million ($125.5 million, net of tax) in 2023.Net income attributa

      7/24/24 4:30:52 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Reports First Quarter 2024 Financial Results

      BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 million ($19.8 million, net of tax), compared to $25.2 million in 2023.Net income attributable to Amedisys, Inc. per diluted share o

      4/24/24 4:45:46 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results

      BATON ROUGE, La., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $19.3 million, which is inclusive of $11.5 million in costs associated with with our merger transactions, compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted s

      2/21/24 4:30:11 PM ET
      $AMED
      Medical/Nursing Services
      Health Care